Beijing Tong Ren Tang Chinese Medicine Company (3613) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
2 Dec, 2025Executive summary
Announcement discloses that unaudited financial information for the three months ended 31 March 2025 has been published by the controlling shareholder, Tong Ren Tang Technologies.
Reference is made to further unaudited results to be announced by the ultimate controlling shareholder, Beijing Tong Ren Tang Company Limited, on the Shanghai Stock Exchange.
Significant events and developments
The announcement is made in compliance with Hong Kong regulatory requirements and references the publication of financial information by the controlling shareholder.
Shareholders and potential investors are advised to exercise caution when dealing in the securities.
Capital allocation and financing
The announcement includes the current composition of the Board, listing executive, non-executive, and independent non-executive directors.
Latest events from Beijing Tong Ren Tang Chinese Medicine Company
- Q1 2026 unaudited results released by controlling shareholder; caution advised for investors.3613
Q1 2026 - Revenue and profit fell, but cash and equity rose; global expansion and innovation prioritized.3613
Q4 2025 - Controlling shareholder released unaudited nine-month 2024 results; caution advised.3613
Q3 2024 - Controlling shareholder released unaudited 9-month 2025 results; parent to follow by 31 Oct.3613
Q3 2025 - Revenue and profit rose, driven by expansion, innovation, and strong cash position.3613
Q2 2025 - Revenue and profit fell over 17% year-over-year, but liquidity and R&D investment stayed strong.3613
Q2 2024 - Revenue up 5.7% but net profit down 10.4% as Overseas sales fell and costs rose.3613
Q4 2024